Treatment of patients with Hodgkin’s lymphoma after progression: chemosensitivity, transplantation and targeted drugs

Rudiuk T., Novosad O., Kriachok I.A.

Summary. Hodgkin’s lymphoma is still considered a curable disease in the world, with up to 90% of patients in the early stages and 70% to 80% of patients in the late stages achieving long-term remission after first-line therapy. After responding to first line therapy about 15–25% of Hodgkin’s lymphoma patients have primary refractory disease or relapse, and about half are diagnosed with chemosensitivity and/or relapse after transplantation. High-dose chemotherapy and autologous hematopoietic stem cell transplantation are highly effective therapies in patients with refractory disease or relapse, leading to long-term survival in a significant number of patients. Patients who are treated prematurely in the presence of high-risk disease, insufficient response to standard first-line therapy, or chemosensitive relapse have a good prognosis. However, in patients with primary chemoresistant disease and in patients with relapse who do not have chemosensitivity, high-dose chemotherapy and autologous hematopoietic stem cell transplantation are not beneficial. Allogeneic hematopoietic stem cell transplantation and/or targeted immunotherapy are performed for this group of patients.

Follow us on social media:
No Comments » Add your
Leave a comment